Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)
Not Applicable
Recruiting
- Conditions
- Vacuum-assisted Biopsy
- Interventions
- Diagnostic Test: Vacuum-assisted biopsy
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 67
- Registration Number
- NCT03876951
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES
Not Applicable
Recruiting
- Conditions
- FES TEP in Detection of Estrogen Receptors
- Interventions
- Other: FES PET
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 25
- Registration Number
- NCT03873428
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, Bourgogne, France
🇫🇷CGFL, Dijon, France
Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)
Recruiting
- Conditions
- Sarcoma
- Interventions
- Biological: Blood samples
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 34
- Registration Number
- NCT03800121
- Locations
- 🇫🇷
CHU de Besançon, Besançon, France
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷CHU de Poitiers, Poitiers, France
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 30
- Registration Number
- NCT03795311
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Validation of a Genetic Signature to Predict the Development of Sarcomas
Completed
- Conditions
- Genetic Signature in Development of Sarcomas
- Interventions
- Biological: blood sample
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 60
- Registration Number
- NCT03625791
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Institu Bergonie, Bordeaux, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Optimizing the Management of Patients With Oral Therapy
Not Applicable
Terminated
- Conditions
- Breast CancerKidney Cancer
- Interventions
- Other: managment of oral therapy
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 101
- Registration Number
- NCT03623490
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 11
- Registration Number
- NCT03607149
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷CH William Morey, Chalon-sur-Saône, France
🇫🇷Centre Universitaire Hospitalier de Dijon, Dijon, France
Evaluation of GEMCITEST in Patients With Pancreatic Cancer and Treated by Chemotherapy
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 100
- Registration Number
- NCT03599154
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma
Active, not recruiting
- Conditions
- Glioblastoma
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 160
- Registration Number
- NCT03481231
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇮🇹Azienda Ospedaliera Università di Padova, Padova, Italy
🇫🇷CHU de DIJON, Dijon, France
Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk
Not Applicable
Recruiting
- Conditions
- To Evaluate the Rate of Digestive and Urinary Toxicity
- Interventions
- Radiation: prostatic boost in brachytherapy with high dose rate (HDR)
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Centre Georges Francois Leclerc
- Target Recruit Count
- 90
- Registration Number
- NCT03417336
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷CGFL, Dijon, France
© Copyright 2025. All Rights Reserved by MedPath